George Frederick Wilkinson

Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ.

Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ.

PLIVA d.d. is a joint stock company incorporated and domiciled in the Republic of Croatia. The registered office is at Vukovarska 49, Zagreb. The Company is the parent of the PLIVA Group (“the Group”). The Group manufactures and supplies a wide range of pharmaceutical products as its core business. Non-core businesses consist of the manufacture and supply of DDDI products (diagnostics, disinfectants, dialysis, and infusions).

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

PLIVA d.d. is a joint stock company incorporated and domiciled in the Republic of Croatia. The registered office is at Vukovarska 49, Zagreb. The Company is the parent of the PLIVA Group (“the Group”). The Group manufactures and supplies a wide range of pharmaceutical products as its core business. Non-core businesses consist of the manufacture and supply of DDDI products (diagnostics, disinfectants, dialysis, and infusions).

PLIVA d.d. is a joint stock company incorporated and domiciled in the Republic of Croatia. The registered office is at Vukovarska 49, Zagreb. The Company is the parent of the PLIVA Group (“the Group”). The Group manufactures and supplies a wide range of pharmaceutical products as its core business. Non-core businesses consist of the manufacture and supply of DDDI products (diagnostics, disinfectants, dialysis, and infusions).

Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ.

Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

PLIVA d.d. is a joint stock company incorporated and domiciled in the Republic of Croatia. The registered office is at Vukovarska 49, Zagreb. The Company is the parent of the PLIVA Group (“the Group”). The Group manufactures and supplies a wide range of pharmaceutical products as its core business. Non-core businesses consist of the manufacture and supply of DDDI products (diagnostics, disinfectants, dialysis, and infusions).